OphtahliX Inc.
AboutSciencePipelineInvestor InformationContact
About Ophthalix About Ophthalix About Ophthalix About Ophthalix About Ophthalix

OphthaliX Inc. (OTCBB:OPLI) is an advanced clinical-stage biopharmaceutical company focused on developing therapeutic products for the treatment of ophthalmic disorders. OphthaliX drug candidate, CF101, an A3 adenosine receptor agonist, is a novel first in class small molecule orally bioavailable drug, which is being developed to treat three ophthalmic indications: dry eye syndrome; glaucoma and uveitis.

Science
The company technology platform is based on the finding that the Gi protein coupled A3 adenosine receptor (A3AR) is highly expressed in inflammatory cells whereas low expression is found in normal body cells. High A3AR expression >>  more...
Pipeline
CF101 is currently being developed by OphthaliX to treat three ophthalmic indications: dry eye syndrome; glaucoma and uveitis. A phase III dry eye syndrome study is currently ongoing, under a US IND, in the US, Europe  >> more...


News
12/05/2013 10:35:03
Third Party Presented New Data at the ARVO 2013 Annual Meeting in Seattle, WA, Validating the use of A3 Adenosine Receptor Agonists for Lowering Intra>> more...
17/03/2013 10:35:03
OphthaliX Inc. Announces the Completion of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study>> more...

Homepage  |  Contact us  |  
only Ophthalix.com